| DDI Drug Name |
DDI Drug ID |
Severity |
Mechanism |
Comorbidity |
REF |
| Sodium bicarbonate |
DMMU6BJ
|
Moderate |
Decreased absorption of Dasatinib due to altered gastric pH caused by Sodium bicarbonate. |
Acidosis [5C73]
|
[15] |
| Metreleptin |
DM1NOEK
|
Moderate |
Increased metabolism of Dasatinib caused by Metreleptin mediated induction of CYP450 enzyme. |
Acute diabete complication [5A2Y]
|
[18] |
| Ivosidenib |
DM8S6T7
|
Major |
Increased risk of prolong QT interval by the combination of Dasatinib and Ivosidenib. |
Acute myeloid leukaemia [2A60]
|
[19] |
| Midostaurin |
DMI6E0R
|
Moderate |
Increased risk of prolong QT interval by the combination of Dasatinib and Midostaurin. |
Acute myeloid leukaemia [2A60]
|
[15] |
| Arn-509 |
DMT81LZ
|
Major |
Increased metabolism of Dasatinib caused by Arn-509 mediated induction of CYP450 enzyme. |
Acute myeloid leukaemia [2A60]
|
[18] |
| Gilteritinib |
DMTI0ZO
|
Moderate |
Increased risk of prolong QT interval by the combination of Dasatinib and Gilteritinib. |
Acute myeloid leukaemia [2A60]
|
[20] |
| Oliceridine |
DM6MDCF
|
Moderate |
Increased risk of prolong QT interval by the combination of Dasatinib and Oliceridine. |
Acute pain [MG31]
|
[15] |
| Ivabradine |
DM0L594
|
Major |
Increased risk of ventricular arrhythmias by the combination of Dasatinib and Ivabradine. |
Angina pectoris [BA40]
|
[21] |
| Dronedarone |
DMA8FS5
|
Major |
Increased risk of prolong QT interval by the combination of Dasatinib and Dronedarone. |
Angina pectoris [BA40]
|
[16] |
| Bedaquiline |
DM3906J
|
Major |
Increased risk of prolong QT interval by the combination of Dasatinib and Bedaquiline. |
Antimicrobial drug resistance [MG50-MG52]
|
[22] |
| Posaconazole |
DMUL5EW
|
Major |
Decreased metabolism of Dasatinib caused by Posaconazole mediated inhibition of CYP450 enzyme. |
Aspergillosis [1F20]
|
[18] |
| Levalbuterol |
DM5YBO1
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Dasatinib and Levalbuterol. |
Asthma [CA23]
|
[23] |
| Roflumilast |
DMPGHY8
|
Moderate |
Additive immunosuppressive effects by the combination of Dasatinib and Roflumilast. |
Asthma [CA23]
|
[21] |
| Lisdexamfetamine |
DM6W8V5
|
Moderate |
Increased risk of prolong QT interval by the combination of Dasatinib and Lisdexamfetamine. |
Attention deficit hyperactivity disorder [6A05]
|
[21] |
| Dalfopristin |
DM4LTKV
|
Moderate |
Decreased metabolism of Dasatinib caused by Dalfopristin mediated inhibition of CYP450 enzyme. |
Bacterial infection [1A00-1C4Z]
|
[18] |
| Troleandomycin |
DMUZNIG
|
Major |
Decreased metabolism of Dasatinib caused by Troleandomycin mediated inhibition of CYP450 enzyme. |
Bacterial infection [1A00-1C4Z]
|
[18] |
| Retigabine |
DMGNYIH
|
Moderate |
Increased risk of prolong QT interval by the combination of Dasatinib and Retigabine. |
Behcet disease [4A62]
|
[15] |
| Cariprazine |
DMJYDVK
|
Moderate |
Decreased metabolism of Dasatinib caused by Cariprazine mediated inhibition of CYP450 enzyme. |
Bipolar disorder [6A60]
|
[21] |
| Pexidartinib |
DMS2J0Z
|
Moderate |
Increased metabolism of Dasatinib caused by Pexidartinib mediated induction of CYP450 enzyme. |
Bone/articular cartilage neoplasm [2F7B]
|
[18] |
| Eribulin |
DM1DX4Q
|
Moderate |
Increased risk of prolong QT interval by the combination of Dasatinib and Eribulin. |
Breast cancer [2C60-2C6Y]
|
[16] |
| Ixabepilone |
DM2OZ3G
|
Moderate |
Decreased metabolism of Dasatinib caused by Ixabepilone mediated inhibition of CYP450 enzyme. |
Breast cancer [2C60-2C6Y]
|
[24] |
| Lapatinib |
DM3BH1Y
|
Moderate |
Increased risk of prolong QT interval by the combination of Dasatinib and Lapatinib. |
Breast cancer [2C60-2C6Y]
|
[15] |
| LY2835219 |
DM93VBZ
|
Moderate |
Decreased metabolism of Dasatinib caused by LY2835219 mediated inhibition of CYP450 enzyme. |
Breast cancer [2C60-2C6Y]
|
[25] |
| Tucatinib |
DMBESUA
|
Major |
Decreased metabolism of Dasatinib caused by Tucatinib mediated inhibition of CYP450 enzyme. |
Breast cancer [2C60-2C6Y]
|
[18] |
| Palbociclib |
DMD7L94
|
Moderate |
Decreased metabolism of Dasatinib caused by Palbociclib mediated inhibition of CYP450 enzyme. |
Breast cancer [2C60-2C6Y]
|
[21] |
| Quinestrol |
DMJ6H1Z
|
Moderate |
Decreased metabolism of Dasatinib caused by Quinestrol mediated inhibition of CYP450 enzyme. |
Breast cancer [2C60-2C6Y]
|
[15] |
| Cabazitaxel |
DMPAZHC
|
Moderate |
Decreased metabolism of Dasatinib caused by Cabazitaxel mediated inhibition of CYP450 enzyme. |
Breast cancer [2C60-2C6Y]
|
[15] |
| Bosutinib |
DMTI8YE
|
Moderate |
Decreased metabolism of Dasatinib caused by Bosutinib mediated inhibition of CYP450 enzyme. |
Breast cancer [2C60-2C6Y]
|
[21] |
| Trastuzumab Emtansine |
DMU1LXS
|
Major |
Increased risk of bleeding by the combination of Dasatinib and Trastuzumab Emtansine. |
Breast cancer [2C60-2C6Y]
|
[18] |
| Macitentan |
DMP79A1
|
Moderate |
Decreased metabolism of Dasatinib caused by Macitentan mediated inhibition of CYP450 enzyme. |
Cardiovascular disease [BA00-BE2Z]
|
[26] |
| PF-04449913 |
DMSB068
|
Moderate |
Increased risk of prolong QT interval by the combination of Dasatinib and PF-04449913. |
Chronic myelomonocytic leukaemia [2A40]
|
[27] |
| Olodaterol |
DM62B78
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Dasatinib and Olodaterol. |
Chronic obstructive pulmonary disease [CA22]
|
[28] |
| Vilanterol |
DMF5EK1
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Dasatinib and Vilanterol. |
Chronic obstructive pulmonary disease [CA22]
|
[23] |
| Indacaterol |
DMQJHR7
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Dasatinib and Indacaterol. |
Chronic obstructive pulmonary disease [CA22]
|
[28] |
| Arformoterol |
DMYM974
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Dasatinib and Arformoterol. |
Chronic obstructive pulmonary disease [CA22]
|
[28] |
| Dihydrocodeine |
DMB0FWL
|
Moderate |
Decreased metabolism of Dasatinib caused by Dihydrocodeine mediated inhibition of CYP450 enzyme. |
Chronic pain [MG30]
|
[18] |
| Regorafenib |
DMHSY1I
|
Major |
Increased risk of bleeding by the combination of Dasatinib and Regorafenib. |
Colorectal cancer [2B91]
|
[15] |
| Probucol |
DMVZQ2M
|
Moderate |
Increased risk of prolong QT interval by the combination of Dasatinib and Probucol. |
Coronary atherosclerosis [BA80]
|
[15] |
| Ardeparin |
DMYRX8B
|
Major |
Increased risk of bleeding by the combination of Dasatinib and Ardeparin. |
Coronary thrombosis [BA43]
|
[15] |
| Pasireotide |
DMHM7JS
|
Major |
Increased risk of prolong QT interval by the combination of Dasatinib and Pasireotide. |
Cushing syndrome [5A70]
|
[16] |
| Lumacaftor |
DMCLWDJ
|
Major |
Increased metabolism of Dasatinib caused by Lumacaftor mediated induction of CYP450 enzyme. |
Cystic fibrosis [CA25]
|
[18] |
| Ivacaftor |
DMZC1HS
|
Moderate |
Decreased metabolism of Dasatinib caused by Ivacaftor mediated inhibition of CYP450 enzyme. |
Cystic fibrosis [CA25]
|
[29] |
| MK-8228 |
DMOB58Q
|
Moderate |
Decreased metabolism of Dasatinib caused by MK-8228 mediated inhibition of CYP450 enzyme. |
Cytomegaloviral disease [1D82]
|
[15] |
| Danaparoid |
DM6CLBN
|
Major |
Increased risk of bleeding by the combination of Dasatinib and Danaparoid. |
Deep vein thrombosis [BD71]
|
[15] |
| Rivaroxaban |
DMQMBZ1
|
Major |
Increased risk of bleeding by the combination of Dasatinib and Rivaroxaban. |
Deep vein thrombosis [BD71]
|
[15] |
| Vilazodone |
DM4LECQ
|
Moderate |
Increased risk of bleeding by the combination of Dasatinib and Vilazodone. |
Depression [6A70-6A7Z]
|
[30] |
| Vortioxetine |
DM6F1PU
|
Moderate |
Increased risk of bleeding by the combination of Dasatinib and Vortioxetine. |
Depression [6A70-6A7Z]
|
[30] |
| Milnacipran |
DMBFE74
|
Moderate |
Increased risk of bleeding by the combination of Dasatinib and Milnacipran. |
Depression [6A70-6A7Z]
|
[30] |
| Desvenlafaxine |
DMHD4PE
|
Moderate |
Increased risk of bleeding by the combination of Dasatinib and Desvenlafaxine. |
Depression [6A70-6A7Z]
|
[30] |
| Polatuzumab vedotin |
DMF6Y0L
|
Moderate |
Decreased metabolism of Dasatinib caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme. |
Diffuse large B-cell lymphoma [2A81]
|
[31] |
| Heme |
DMGC287
|
Moderate |
Increased risk of bleeding by the combination of Dasatinib and Heme. |
Discovery agent [N.A.]
|
[32] |
| [3H]estrone-3-sulphate |
DMGPF0N
|
Moderate |
Decreased metabolism of Dasatinib caused by [3H]estrone-3-sulphate mediated inhibition of CYP450 enzyme. |
Discovery agent [N.A.]
|
[18] |
| SODIUM CITRATE |
DMHPD2Y
|
Moderate |
Decreased absorption of Dasatinib due to altered gastric pH caused by SODIUM CITRATE. |
Discovery agent [N.A.]
|
[15] |
| Apigenin |
DMI3491
|
Minor |
Increased risk of bleeding by the combination of Dasatinib and Apigenin. |
Discovery agent [N.A.]
|
[33] |
| Tetrabenazine |
DMYWQ0O
|
Moderate |
Increased risk of prolong QT interval by the combination of Dasatinib and Tetrabenazine. |
Dissociative neurological symptom disorder [6B60]
|
[16] |
| Ingrezza |
DMVPLNC
|
Moderate |
Increased risk of prolong QT interval by the combination of Dasatinib and Ingrezza. |
Dystonic disorder [8A02]
|
[34] |
| Cenobamate |
DM8KLU9
|
Moderate |
Increased metabolism of Dasatinib caused by Cenobamate mediated induction of CYP450 enzyme. |
Epilepsy/seizure [8A61-8A6Z]
|
[18] |
| Fosphenytoin |
DMOX3LB
|
Major |
Increased metabolism of Dasatinib caused by Fosphenytoin mediated induction of CYP450 enzyme. |
Epilepsy/seizure [8A61-8A6Z]
|
[18] |
| Eslicarbazepine |
DMZREFQ
|
Moderate |
Increased metabolism of Dasatinib caused by Eslicarbazepine mediated induction of CYP450 enzyme. |
Epilepsy/seizure [8A61-8A6Z]
|
[18] |
| Bay 80-6946 |
DMLOS5R
|
Moderate |
Decreased metabolism of Dasatinib caused by Bay 80-6946 mediated inhibition of CYP450 enzyme. |
Follicular lymphoma [2A80]
|
[35] |
| Tazemetostat |
DMWP1BH
|
Moderate |
Decreased metabolism of Dasatinib caused by Tazemetostat mediated inhibition of CYP450 enzyme. |
Follicular lymphoma [2A80]
|
[36] |
| Solifenacin |
DMG592Q
|
Moderate |
Increased risk of prolong QT interval by the combination of Dasatinib and Solifenacin. |
Functional bladder disorder [GC50]
|
[15] |
| Mirabegron |
DMS1GYT
|
Minor |
Decreased metabolism of Dasatinib caused by Mirabegron mediated inhibition of CYP450 enzyme. |
Functional bladder disorder [GC50]
|
[37] |
| Dexlansoprazole |
DM1DBV5
|
Major |
Decreased absorption of Dasatinib due to altered gastric pH caused by Dexlansoprazole. |
Gastro-oesophageal reflux disease [DA22]
|
[15] |
| Ripretinib |
DM958QB
|
Moderate |
Decreased metabolism of Dasatinib caused by Ripretinib mediated inhibition of CYP450 enzyme. |
Gastrointestinal stromal tumour [2B5B]
|
[18] |
| Sunitinib |
DMCBJSR
|
Moderate |
Increased risk of prolong QT interval by the combination of Dasatinib and Sunitinib. |
Gastrointestinal stromal tumour [2B5B]
|
[15] |
| Avapritinib |
DMK2GZX
|
Major |
Increased risk of bleeding by the combination of Dasatinib and Avapritinib. |
Gastrointestinal stromal tumour [2B5B]
|
[15] |
| Colchicine |
DM2POTE
|
Moderate |
Decreased metabolism of Dasatinib caused by Colchicine mediated inhibition of CYP450 enzyme. |
Gout [FA25]
|
[15] |
| Boceprevir |
DMBSHMF
|
Major |
Decreased metabolism of Dasatinib caused by Boceprevir mediated inhibition of CYP450 enzyme. |
Hepatitis virus infection [1E50-1E51]
|
[15] |
| Telaprevir |
DMMRV29
|
Major |
Decreased metabolism of Dasatinib caused by Telaprevir mediated inhibition of CYP450 enzyme. |
Hepatitis virus infection [1E50-1E51]
|
[18] |
| MK-1439 |
DM215WE
|
Minor |
Decreased metabolism of Dasatinib caused by MK-1439 mediated inhibition of CYP450 enzyme. |
Human immunodeficiency virus disease [1C60-1C62]
|
[38] |
| Fosamprenavir |
DM4W9B3
|
Major |
Decreased metabolism of Dasatinib caused by Fosamprenavir mediated inhibition of CYP450 enzyme. |
Human immunodeficiency virus disease [1C60-1C62]
|
[18] |
| Fostemsavir |
DM50ILT
|
Moderate |
Increased risk of prolong QT interval by the combination of Dasatinib and Fostemsavir. |
Human immunodeficiency virus disease [1C60-1C62]
|
[39] |
| Cobicistat |
DM6L4H2
|
Major |
Decreased metabolism of Dasatinib caused by Cobicistat mediated inhibition of CYP450 enzyme. |
Human immunodeficiency virus disease [1C60-1C62]
|
[18] |
| Dolutegravir |
DMCZGRE
|
Minor |
Decreased metabolism of Dasatinib caused by Dolutegravir mediated inhibition of CYP450 enzyme. |
Human immunodeficiency virus disease [1C60-1C62]
|
[40] |
| Etravirine |
DMGV8QU
|
Moderate |
Increased metabolism of Dasatinib caused by Etravirine mediated induction of CYP450 enzyme. |
Human immunodeficiency virus disease [1C60-1C62]
|
[41] |
| Rilpivirine |
DMJ0QOW
|
Moderate |
Increased risk of prolong QT interval by the combination of Dasatinib and Rilpivirine. |
Human immunodeficiency virus disease [1C60-1C62]
|
[15] |
| Darunavir |
DMN3GCH
|
Major |
Decreased metabolism of Dasatinib caused by Darunavir mediated inhibition of CYP450 enzyme. |
Human immunodeficiency virus disease [1C60-1C62]
|
[18] |
| Maraviroc |
DMTL94F
|
Moderate |
Decreased clearance of Dasatinib due to the transporter inhibition by Maraviroc. |
Human immunodeficiency virus disease [1C60-1C62]
|
[42] |
| Teriflunomide |
DMQ2FKJ
|
Major |
Additive myelosuppressive effects by the combination of Dasatinib and Teriflunomide. |
Hyper-lipoproteinaemia [5C80]
|
[43] |
| BMS-201038 |
DMQTAGO
|
Moderate |
Decreased metabolism of Dasatinib caused by BMS-201038 mediated inhibition of CYP450 enzyme. |
Hyper-lipoproteinaemia [5C80]
|
[44] |
| Sodium zirconium cyclosilicate |
DMCSLZ4
|
Moderate |
Decreased absorption of Dasatinib due to altered gastric pH caused by Sodium zirconium cyclosilicate. |
Hyperkalaemia [5C76]
|
[21] |
| Retapamulin |
DM9JXB7
|
Minor |
Decreased metabolism of Dasatinib caused by Retapamulin mediated inhibition of CYP450 enzyme. |
Impetigo [1B72]
|
[45] |
| Lesinurad |
DMUR64T
|
Moderate |
Increased metabolism of Dasatinib caused by Lesinurad mediated induction of CYP450 enzyme. |
Inborn purine/pyrimidine/nucleotide metabolism error [5C55]
|
[18] |
| Berotralstat |
DMWA2DZ
|
Moderate |
Decreased metabolism of Dasatinib caused by Berotralstat mediated inhibition of CYP450 enzyme. |
Innate/adaptive immunodeficiency [4A00]
|
[15] |
| Suvorexant |
DM0E6S3
|
Moderate |
Decreased metabolism of Dasatinib caused by Suvorexant mediated inhibition of CYP450 enzyme. |
Insomnia [7A00-7A0Z]
|
[18] |
| Amobarbital |
DM0GQ8N
|
Moderate |
Increased metabolism of Dasatinib caused by Amobarbital mediated induction of CYP450 enzyme. |
Insomnia [7A00-7A0Z]
|
[18] |
| Polyethylene glycol |
DM4I1JP
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Dasatinib and Polyethylene glycol. |
Irritable bowel syndrome [DD91]
|
[21] |
| Phenolphthalein |
DM5SICT
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Dasatinib and Phenolphthalein. |
Irritable bowel syndrome [DD91]
|
[16] |
| Naloxegol |
DML0B41
|
Minor |
Decreased metabolism of Dasatinib caused by Naloxegol mediated inhibition of CYP450 enzyme. |
Large intestine motility disorder [DB32]
|
[46] |
| Pemigatinib |
DM819JF
|
Moderate |
Decreased metabolism of Dasatinib caused by Pemigatinib mediated inhibition of CYP450 enzyme. |
Liver cancer [2C12]
|
[21] |
| Glycerol phenylbutyrate |
DMDGRQO
|
Moderate |
Increased metabolism of Dasatinib caused by Glycerol phenylbutyrate mediated induction of CYP450 enzyme. |
Liver disease [DB90-DB9Z]
|
[18] |
| Denosumab |
DMNI0KO
|
Moderate |
Additive immunosuppressive effects by the combination of Dasatinib and Denosumab. |
Low bone mass disorder [FB83]
|
[47] |
| Crizotinib |
DM4F29C
|
Major |
Increased risk of prolong QT interval by the combination of Dasatinib and Crizotinib. |
Lung cancer [2C25]
|
[48] |
| Brigatinib |
DM7W94S
|
Moderate |
Increased metabolism of Dasatinib caused by Brigatinib mediated induction of CYP450 enzyme. |
Lung cancer [2C25]
|
[18] |
| Ceritinib |
DMB920Z
|
Major |
Decreased metabolism of Dasatinib caused by Ceritinib mediated inhibition of CYP450 enzyme. |
Lung cancer [2C25]
|
[18] |
| PF-06463922 |
DMKM7EW
|
Moderate |
Increased metabolism of Dasatinib caused by PF-06463922 mediated induction of CYP450 enzyme. |
Lung cancer [2C25]
|
[18] |
| Osimertinib |
DMRJLAT
|
Major |
Increased risk of prolong QT interval by the combination of Dasatinib and Osimertinib. |
Lung cancer [2C25]
|
[49] |
| Pralsetinib |
DMWU0I2
|
Moderate |
Decreased metabolism of Dasatinib caused by Pralsetinib mediated inhibition of CYP450 enzyme. |
Lung cancer [2C25]
|
[50] |
| Selpercatinib |
DMZR15V
|
Major |
Increased risk of prolong QT interval by the combination of Dasatinib and Selpercatinib. |
Lung cancer [2C25]
|
[21] |
| Hydroxychloroquine |
DMSIVND
|
Major |
Increased risk of prolong QT interval by the combination of Dasatinib and Hydroxychloroquine. |
Malaria [1F40-1F45]
|
[51] |
| Inotuzumab ozogamicin |
DMAC130
|
Moderate |
Increased risk of prolong QT interval by the combination of Dasatinib and Inotuzumab ozogamicin. |
Malignant haematopoietic neoplasm [2B33]
|
[21] |
| Idelalisib |
DM602WT
|
Major |
Decreased metabolism of Dasatinib caused by Idelalisib mediated inhibition of CYP450 enzyme. |
Mature B-cell leukaemia [2A82]
|
[18] |
| GDC-0199 |
DMH0QKA
|
Moderate |
Decreased metabolism of Dasatinib caused by GDC-0199 mediated inhibition of CYP450 enzyme. |
Mature B-cell leukaemia [2A82]
|
[18] |
| IPI-145 |
DMWA24P
|
Moderate |
Decreased metabolism of Dasatinib caused by IPI-145 mediated inhibition of CYP450 enzyme. |
Mature B-cell leukaemia [2A82]
|
[15] |
| Acalabrutinib |
DM7GCVW
|
Major |
Increased risk of bleeding by the combination of Dasatinib and Acalabrutinib. |
Mature B-cell lymphoma [2A85]
|
[15] |
| Ibrutinib |
DMHZCPO
|
Major |
Increased risk of bleeding by the combination of Dasatinib and Ibrutinib. |
Mature B-cell lymphoma [2A85]
|
[15] |
| Ponatinib |
DMYGJQO
|
Major |
Increased risk of bleeding by the combination of Dasatinib and Ponatinib. |
Mature B-cell lymphoma [2A85]
|
[15] |
| Arry-162 |
DM1P6FR
|
Major |
Increased risk of bleeding by the combination of Dasatinib and Arry-162. |
Melanoma [2C30]
|
[15] |
| Vemurafenib |
DM62UG5
|
Major |
Increased risk of prolong QT interval by the combination of Dasatinib and Vemurafenib. |
Melanoma [2C30]
|
[16] |
| Selumetinib |
DMC7W6R
|
Moderate |
Decreased metabolism of Dasatinib caused by Selumetinib mediated inhibition of CYP450 enzyme. |
Melanoma [2C30]
|
[52] |
| LGX818 |
DMNQXV8
|
Moderate |
Increased risk of prolong QT interval by the combination of Dasatinib and LGX818. |
Melanoma [2C30]
|
[53] |
| Dabrafenib |
DMX6OE3
|
Moderate |
Increased metabolism of Dasatinib caused by Dabrafenib mediated induction of CYP450 enzyme. |
Melanoma [2C30]
|
[21] |
| Danazol |
DML8KTN
|
Moderate |
Decreased metabolism of Dasatinib caused by Danazol mediated inhibition of CYP450 enzyme. |
Menstrual cycle bleeding disorder [GA20]
|
[15] |
| Flibanserin |
DM70DTN
|
Moderate |
Decreased metabolism of Dasatinib caused by Flibanserin mediated inhibition of CYP450 enzyme. |
Mood disorder [6A60-6E23]
|
[54] |
| Panobinostat |
DM58WKG
|
Major |
Increased risk of prolong QT interval by the combination of Dasatinib and Panobinostat. |
Multiple myeloma [2A83]
|
[55] |
| Tecfidera |
DM2OVDT
|
Moderate |
Additive immunosuppressive effects by the combination of Dasatinib and Tecfidera. |
Multiple sclerosis [8A40]
|
[56] |
| Siponimod |
DM2R86O
|
Major |
Additive immunosuppressive effects by the combination of Dasatinib and Siponimod. |
Multiple sclerosis [8A40]
|
[18] |
| Fingolimod |
DM5JVAN
|
Major |
Additive immunosuppressive effects by the combination of Dasatinib and Fingolimod. |
Multiple sclerosis [8A40]
|
[57] |
| Ozanimod |
DMT6AM2
|
Major |
Additive immunosuppressive effects by the combination of Dasatinib and Ozanimod. |
Multiple sclerosis [8A40]
|
[21] |
| Romidepsin |
DMT5GNL
|
Moderate |
Increased risk of prolong QT interval by the combination of Dasatinib and Romidepsin. |
Mycosis fungoides [2B01]
|
[15] |
| Prasugrel |
DM7MT6E
|
Major |
Increased risk of bleeding by the combination of Dasatinib and Prasugrel. |
Myocardial infarction [BA41-BA43]
|
[15] |
| Entrectinib |
DMMPTLH
|
Moderate |
Increased risk of prolong QT interval by the combination of Dasatinib and Entrectinib. |
Non-small cell lung cancer [2C25]
|
[18] |
| Lofexidine |
DM1WXA6
|
Moderate |
Increased risk of prolong QT interval by the combination of Dasatinib and Lofexidine. |
Opioid use disorder [6C43]
|
[16] |
| Nepafenac |
DMYK490
|
Moderate |
Increased risk of bleeding by the combination of Dasatinib and Nepafenac. |
Osteoarthritis [FA00-FA05]
|
[58] |
| Rucaparib |
DM9PVX8
|
Moderate |
Increased risk of prolong QT interval by the combination of Dasatinib and Rucaparib. |
Ovarian cancer [2C73]
|
[15] |
| Triclabendazole |
DMPWGBR
|
Moderate |
Increased risk of prolong QT interval by the combination of Dasatinib and Triclabendazole. |
Parasitic worm infestation [1F90]
|
[15] |
| Pimavanserin |
DMR7IVC
|
Moderate |
Increased risk of prolong QT interval by the combination of Dasatinib and Pimavanserin. |
Parkinsonism [8A00]
|
[59] |
| Abametapir |
DM2RX0I
|
Moderate |
Decreased metabolism of Dasatinib caused by Abametapir mediated inhibition of CYP450 enzyme. |
Pediculosis [1G00]
|
[60] |
| Macimorelin |
DMQYJIR
|
Major |
Increased risk of prolong QT interval by the combination of Dasatinib and Macimorelin. |
Pituitary gland disorder [5A60-5A61]
|
[61] |
| Lonafarnib |
DMGM2Z6
|
Major |
Decreased metabolism of Dasatinib caused by Lonafarnib mediated inhibition of CYP450 enzyme. |
Premature ageing appearance [LD2B]
|
[18] |
| Degarelix |
DM3O8QY
|
Moderate |
Increased risk of prolong QT interval by the combination of Dasatinib and Degarelix. |
Prostate cancer [2C82]
|
[21] |
| ABIRATERONE |
DM8V75C
|
Moderate |
Increased risk of prolong QT interval by the combination of Dasatinib and ABIRATERONE. |
Prostate cancer [2C82]
|
[21] |
| Enzalutamide |
DMGL19D
|
Major |
Increased metabolism of Dasatinib caused by Enzalutamide mediated induction of CYP450 enzyme. |
Prostate cancer [2C82]
|
[18] |
| Relugolix |
DMK7IWL
|
Moderate |
Increased risk of prolong QT interval by the combination of Dasatinib and Relugolix. |
Prostate cancer [2C82]
|
[21] |
| Levomepromazine |
DMIKFEL
|
Moderate |
Increased risk of prolong QT interval by the combination of Dasatinib and Levomepromazine. |
Psychotic disorder [6A20-6A25]
|
[15] |
| Everolimus |
DM8X2EH
|
Moderate |
Decreased metabolism of Dasatinib caused by Everolimus mediated inhibition of CYP450 enzyme. |
Renal cell carcinoma [2C90]
|
[62] |
| Axitinib |
DMGVH6N
|
Moderate |
Decreased metabolism of Dasatinib caused by Axitinib mediated inhibition of CYP450 enzyme. |
Renal cell carcinoma [2C90]
|
[21] |
| Temsirolimus |
DMS104F
|
Moderate |
Decreased metabolism of Dasatinib caused by Temsirolimus mediated inhibition of CYP450 enzyme. |
Renal cell carcinoma [2C90]
|
[63] |
| Canakinumab |
DM8HLO5
|
Moderate |
Additive immunosuppressive effects by the combination of Dasatinib and Canakinumab. |
Rheumatoid arthritis [FA20]
|
[64] |
| Rilonacept |
DMGLUQS
|
Moderate |
Additive immunosuppressive effects by the combination of Dasatinib and Rilonacept. |
Rheumatoid arthritis [FA20]
|
[64] |
| Golimumab |
DMHZV7X
|
Major |
Additive immunosuppressive effects by the combination of Dasatinib and Golimumab. |
Rheumatoid arthritis [FA20]
|
[65] |
| Iloperidone |
DM6AUFY
|
Major |
Increased risk of prolong QT interval by the combination of Dasatinib and Iloperidone. |
Schizophrenia [6A20]
|
[16] |
| Paliperidone |
DM7NPJS
|
Moderate |
Increased risk of prolong QT interval by the combination of Dasatinib and Paliperidone. |
Schizophrenia [6A20]
|
[15] |
| Amisulpride |
DMSJVAM
|
Major |
Increased risk of prolong QT interval by the combination of Dasatinib and Amisulpride. |
Schizophrenia [6A20]
|
[66] |
| Asenapine |
DMSQZE2
|
Moderate |
Increased risk of prolong QT interval by the combination of Dasatinib and Asenapine. |
Schizophrenia [6A20]
|
[16] |
| Anthrax vaccine |
DM9GSWY
|
Moderate |
Antagonize the effect of Dasatinib when combined with Anthrax vaccine. |
Sepsis [1G40-1G41]
|
[67] |
| Voxelotor |
DMCS6M5
|
Moderate |
Decreased metabolism of Dasatinib caused by Voxelotor mediated inhibition of CYP450 enzyme. |
Sickle-cell disorder [3A51]
|
[15] |
| LDE225 |
DMM9F25
|
Moderate |
Decreased metabolism of Dasatinib caused by LDE225 mediated inhibition of CYP450 enzyme. |
Skin cancer [2C30-2C37]
|
[68] |
| Telotristat ethyl |
DMDIYFZ
|
Moderate |
Increased metabolism of Dasatinib caused by Telotristat ethyl mediated induction of CYP450 enzyme. |
Small intestine developmental anomaly [DA90]
|
[18] |
| Larotrectinib |
DM26CQR
|
Moderate |
Decreased metabolism of Dasatinib caused by Larotrectinib mediated inhibition of CYP450 enzyme. |
Solid tumour/cancer [2A00-2F9Z]
|
[18] |
| Trabectedin |
DMG3Y89
|
Moderate |
Decreased metabolism of Dasatinib caused by Trabectedin mediated inhibition of CYP450 enzyme. |
Solid tumour/cancer [2A00-2F9Z]
|
[21] |
| Armodafinil |
DMGB035
|
Moderate |
Increased metabolism of Dasatinib caused by Armodafinil mediated induction of CYP450 enzyme. |
Solid tumour/cancer [2A00-2F9Z]
|
[18] |
| Vandetanib |
DMRICNP
|
Major |
Increased risk of prolong QT interval by the combination of Dasatinib and Vandetanib. |
Solid tumour/cancer [2A00-2F9Z]
|
[16] |
| Triptorelin |
DMTK4LS
|
Moderate |
Increased risk of prolong QT interval by the combination of Dasatinib and Triptorelin. |
Solid tumour/cancer [2A00-2F9Z]
|
[21] |
| Pitolisant |
DM8RFNJ
|
Moderate |
Increased risk of prolong QT interval by the combination of Dasatinib and Pitolisant. |
Somnolence [MG42]
|
[18] |
| Telavancin |
DM58VQX
|
Moderate |
Increased risk of prolong QT interval by the combination of Dasatinib and Telavancin. |
Staphylococcal/streptococcal disease [1B5Y]
|
[15] |
| Plicamycin |
DM7C8YV
|
Major |
Increased risk of bleeding by the combination of Dasatinib and Plicamycin. |
Testicular cancer [2C80]
|
[15] |
| Fostamatinib |
DM6AUHV
|
Moderate |
Decreased metabolism of Dasatinib caused by Fostamatinib mediated inhibition of CYP450 enzyme. |
Thrombocytopenia [3B64]
|
[69] |
| Apixaban |
DM89JLN
|
Major |
Increased risk of bleeding by the combination of Dasatinib and Apixaban. |
Thrombosis [DB61-GB90]
|
[15] |
| Cangrelor |
DM8JRH0
|
Major |
Increased risk of bleeding by the combination of Dasatinib and Cangrelor. |
Thrombosis [DB61-GB90]
|
[15] |
| Brilinta |
DMBR01X
|
Major |
Increased risk of bleeding by the combination of Dasatinib and Brilinta. |
Thrombosis [DB61-GB90]
|
[15] |
| Lenvatinib |
DMB1IU4
|
Moderate |
Increased risk of prolong QT interval by the combination of Dasatinib and Lenvatinib. |
Thyroid cancer [2D10]
|
[15] |
| Cabozantinib |
DMIYDT4
|
Major |
Increased risk of prolong QT interval by the combination of Dasatinib and Cabozantinib. |
Thyroid cancer [2D10]
|
[21] |
| Saxagliptin |
DMGXENV
|
Moderate |
Decreased metabolism of Dasatinib caused by Saxagliptin mediated inhibition of CYP450 enzyme. |
Type 2 diabetes mellitus [5A11]
|
[21] |
| Elagolix |
DMB2C0E
|
Moderate |
Increased metabolism of Dasatinib caused by Elagolix mediated induction of CYP450 enzyme. |
Uterine fibroid [2E86]
|
[18] |
| Betrixaban |
DM2C4RF
|
Major |
Increased risk of bleeding by the combination of Dasatinib and Betrixaban. |
Venous thromboembolism [BD72]
|
[15] |
| Valganciclovir |
DMS2IUH
|
Moderate |
Additive myelosuppressive effects by the combination of Dasatinib and Valganciclovir. |
Virus infection [1A24-1D9Z]
|
[18] |
| ----------- |
|
|
|
|
|
